Shares of China-based biotech company Zai Lab Limited (ZLAB) are slipping nearly 18% on Wednesday morning despite no stock related news to hurt the shares.
ZLAB is currently trading at $51.50, down $11.19 or 17.85%, on the Nasdaq.
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, and infectious diseases primarily in Greater China.
For comments and feedback contact: editorial@rttnews.com
Business News